<DOC>
	<DOCNO>NCT00000384</DOCNO>
	<brief_summary>The purpose study compare 3 treatment child OCD : medication ( sertraline , SER ) alone vs OCD-specific therapy ( Cognitive Behavior Therapy , CBT ) v medication plus therapy . Some patient receive inactive placebo ( PBO ) instead medication and/or Educational Support ( ES , non-psychological treatment ) instead therapy . One 200 child suffer OCD , receive appropriate treatment . Both CBT medication seem effective , effectiveness , alone combination , evaluate . There 2 phase trial . In Phase I child receive 1 follow 6 treatment 12 week : 1 ) SER alone ; 2 ) pill PBO alone ; 3 ) CBT alone ; 4 ) SER plus CBT ; 5 ) SER plus ES ; 6 ) pill PBO plus ES . If child responds treatment , he/she go Phase II treatment slowly reduce , stop ( discontinue ) , time test treatment 's durability . The child evaluate Weeks 1 , 4 , 8 , 12 ( Phase I treatment ) , Weeks 16 , 20 , 24 , 28 ( Phase II discontinuation ) see effective durable treatment treat child 's OCD . A child may eligible study he/she : Has obsessive-compulsive disorder ( OCD ) 8 - 16 year old .</brief_summary>
	<brief_title>Treatment Obsessive-Compulsive Disorder ( OCD ) Children</brief_title>
	<detailed_description>To contrast degree durability improvement pediatric obsessive-compulsive disorder ( OCD ) , patient treat 1 6 condition ( 3 active treatment 3 control treatment ) : sertraline alone ( SER ) , OCD-specific Cognitive Behavior Therapy ( CBT ) , SER CBT ( SER plus CBT ) , pill placebo ( PBO ) , pill PBO plus Educational Support ( ES ) , SER plus ES . One 200 youth suffers OCD , yet relatively receive appropriate treatment . Both CBT medication appear beneficial controlled study ; however , relative efficacy CBT medication , alone combination ( COMB ) unknown . Thus , well-designed treatment outcome study necessary improve care youth OCD . The experimental design cover 2 phase . Phase I 2 ( site ) x 2 ( SER pill PBO ) x 3 ( CBT , ES non- psychosocial treatment ) x 5 ( repeat measure ) factorial 12-week comparison SER , CBT , COMB control condition . In Phase II , responder advance 16-week discontinuation study assess treatment durability . The primary outcome measure Yale-Brown Obsessive-Compulsive Scale . Assessments blind treatment status take place Week 0 ( pretreatment ) ; Weeks 1 , 4 , 8 , 12 ( Phase I treatment ) ; Weeks 16 , 20 , 24 28 ( Phase II discontinuation ) . Besides address comparative efficacy durability specify treatment , investigator also examine time-action effect , differential effect specific aspect OCD , include functional impairment , predictor response treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Patients must : DSMIV diagnosed OCD .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Adolescence</keyword>
	<keyword>Child</keyword>
	<keyword>Cognitive Therapy</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Obsessive-Compulsive Disorder</keyword>
	<keyword>Placebos</keyword>
	<keyword>Sertraline</keyword>
	<keyword>Patient Education</keyword>
	<keyword>Psychotherapy</keyword>
</DOC>